ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

ClinicalTrials.gov ID: NCT04368559

Public ClinicalTrials.gov record NCT04368559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

Study identification

NCT ID
NCT04368559
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mundipharma Research Limited
Industry
Enrollment
602 participants

Conditions and interventions

Interventions

  • Fluconazole Drug
  • Intravenous Placebo Drug
  • Oral Placebo Drug
  • Posaconazole Drug
  • Rezafungin for Injection Drug
  • Trimethoprim-sulfamethoxazole (TMP/SMX) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 10, 2020
Primary completion
Jan 28, 2026
Completion
Jan 28, 2026
Last update posted
Apr 12, 2026

2020 – 2026

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
16
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
UCLA Center for Health Sciences Los Angeles California 90095
Stanford University School of Medicine Stanford California 94304
Augusta University Medical Center Augusta Georgia 30912
Rush University Medical Center Chicago Illinois 60612
University of Chicago Chicago Illinois 60637
University of Maryland Medical Center Baltimore Maryland 21201
John Hopkins Baltimore Maryland 21218
Massachusetts General Hospital Boston Massachusetts 02114
University of Minnesota Physicians Minneapolis Minnesota 55455
Mayo Clinic Rochester Minnesota 55905
Mary Hitchcock Memorial Hospital Dartmouth-Hitchcock Lebanon New Hampshire 03756
Hackensack University Medical Center Hackensack New Jersey 07601
Stony Brook University Hospital Stony Brook New York 11794
The University of Oklahoma College of Medicine Oklahoma City Oklahoma 73104
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
VCU Medical Center Main Hospital Richmond Virginia 23219
Fred Hutchinson Cancer Center Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04368559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04368559 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →